MYD88 L265P mutation and CDKN2A loss as early mutational events in primary central nervous system lymphomas.

e14041 Background: The genetic alterations that define PCNSL are beginning to be identified, and the genomic evolution that conveys susceptibility or resistance to treatment in recurrent disease is unknown. Methods: We performed whole-exome sequencing on 36 PCNSL patients and 1 patient with EBV-positive disease. Targeted MYD88 sequencing was performed on a validation cohort consisting of 28 patients with PCNSL. We also performed whole-exome...